BRAF Inhibitor Encorafenib And Cetuximab Real Life Investigation of Next Generation CRC Treatment
Recruiting · NCT04673955 · Observational (researchers observe without assigning treatment) · Lead sponsor: Pierre Fabre Pharma GmbH
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
The presence of a BRAFV600E mutation is a marker of poor prognosis in patients with mCRC and associated with a median overall survival (mOS) of approximately 12 to 14 months compared to 20 to 25 months for patients with BRAF wild-type tumours. After 1st line therapy, treatment outcomes with standard therapy are poor in patients with BRAF-mutated mCRC, with response rates (ORR) of ≤ 11%, a median progression-free survival (mPFS) between 1.8 and 2.8 months, and a mOS between 4.1 and 6.2 months. Failure to achieve adequate survival outcomes with standard treatment regimens in patients with BRAF-mutated mCRC has encouraged efforts to combine multiple targeted therapies: With 665 randomized patients, the BEACON CRC trial represents the largest trial and is currently the only phase III study in patients with BRAFV600E-mutant mCRC. BERING CRC - designed as a prospective (allowing initial retrospective documentation), longitudinal, non-interventional study - will investigate the real-world effectiveness, quality of life, safety and tolerability of encorafenib and cetuximab in BRAFV600E-mutant mCRC patients, who have received prior systemic therapy. Data from this study will contribute to a deeper understanding and characterization to the everyday use of encorafenib and cetuximab in a broader patient population in the German, Austrian, and Swiss routine setting.
Who can take part
Inclusion criteria
- Written informed consent of the patient with regard to the pseudonymized documentation of his/her data in the frame of this non-interventional study
- Legally capable patient ≥ 18 years of age (no upper limit)
- Metastatic colorectal carcinoma with BRAFV600E-mutation, pretreated with systemic therapy
- Decision was taken to treat the patient with the doublet therapy (encorafenib and cetuximab) in accordance with the current SmPC and by prescription; this decision was taken prior to and independent from the inclusion into the study;
- Treatment with the doublet therapy (encorafenib plus cetuximab) has been started ≤ 3 months prior to providing written informed consent for this study or is planned to be started in the near future.
Exclusion criteria
- More than 2 prior systemic regimens in the metastatic setting (adjuvant systemic therapy with relapse ≤ 6 months will be counted as metastatic treatment line; maintenance treatment will not be counted as separate metastatic treatment line)
- Prior treatment with any RAF-inhibitor or MEK-inhibitor.
- Presence of any contraindication with regard to the doublet therapy (encorafenib plus cetuximab) as specified in the corresponding SmPCs
- Current or upcoming participation in an interventional clinical trial
- Current or upcoming systemic treatment of any other tumor than metastatic colorectal carcinoma
- Prisoners or persons who are compulsorily detained (involuntarily incarcerated).
Where it is running
60 locations listed.
- Hospital - Aschaffenburg, Germany
- Medical Care Centre - Berlin, Germany
- Practice - Berlin, Germany
- Practice - Berlin, Germany
- Clinic - Berlin, Germany
- Private Practice - Berlin, Germany
- Private Practice - Dresden, Germany
- Hospital - Esslingen am Neckar, Germany
- Practice - Hamburg, Germany
- Practice - Hamburg, Germany
- Private Practice - Heidelberg, Germany
- Private Practice - Leer, Germany
- Private Practice - Lübeck, Germany
- Private Practice - Naunhof, Germany
- Private Practice - Offenburg, Germany
- Private Practice - Oldenburg in Holstein, Germany
- Private Practice - Schorndorf, Germany
- Clinic - Vienna, Austria
- Private Practice - Würzburg, Germany
- Practice - Offenburg, Baden-Wurttemberg, Germany
- Medical Care Centre - Ulm, Baden-Wurttemberg, Germany
- Clinic - Ulm, Baden-Wurttemberg, Germany
- Practice - Augsburg, Bavaria, Germany
- Practice - Donauwörth, Bavaria, Germany
- Clinic - Erlangen, Bavaria, Germany
- Practice - München, Bavaria, Germany
- Practice - Würzburg, Bavaria, Germany
- Medical Car Centre - Aschaffenburg, Bayer, Germany
- Medical Care Centre - Potsdam, Brandenburg, Germany
- Practice - Celle, Lower Saxony, Germany
- Medical Care Centre - Goslar, Lower Saxony, Germany
- Practice - Göttingen, Lower Saxony, Germany
- Medical Practice - Hanover, Lower Saxony, Germany
- Practice - Hanover, Lower Saxony, Germany
- Practice - Leer, Lower Saxony, Germany
- Clinic - Weißenfels, Lower Saxony, Germany
- Medical Practice - Wilhelmshaven, Lower Saxony, Germany
- Practice - Rostock, Mecklenburg-Vorpommern, Germany
- Practice - Rostock, Mecklenburg-Vorpommern, Germany
- Clinic - Rostock, Melcklenburg-Vorpommern, Germany
- Clinic - Aachen, North Rhine-Westphalia, Germany
- Clinic - Bochum, North Rhine-Westphalia, Germany
- Practice - Bonn, North Rhine-Westphalia, Germany
- Clinic - Bonn, North Rhine-Westphalia, Germany
- Practice - Bottrop, North Rhine-Westphalia, Germany
- Clinic - Essen, North Rhine-Westphalia, Germany
- Practice - Moers, North Rhine-Westphalia, Germany
- Medical Care Centre - Mönchengladbach, North Rhine-Westphalia, Germany
- Medical Care Centre - Mülheim, North Rhine-Westphalia, Germany
- Medical Care Centre - Neuss, North Rhine-Westphalia, Germany
- Clinic - Paderborn, North Rhine-Westphalia, Germany
- Medical Care Centre - Porta Westfalica, North Rhine-Westphalia, Germany
- Practice - Stolberg, North Rhine-Westphalia, Germany
- Practice - Troisdorf, North Rhine-Westphalia, Germany
- Clinic - Wuppertal, North Rhine-Westphalia, Germany
- Practice - Bad Kreuznach, Rhineland-Palatinate, Germany
- Practice - Kaiserslautern, Rhineland-Palatinate, Germany
- Practice - Worms, Rhineland-Palatinate, Germany
- Clinic - Saarbrücken, Saarland, Germany
- Practice - Dresden, Saxony, Germany
Showing 60 of 70 listed sites. See the official record for the complete list.
Read the full protocol, contacts and eligibility on ClinicalTrials.gov →